Search results
Adma Biologics (ADMA) Upgraded to Strong Buy: Here's Why
Adma Biologics (ADMA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is
ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance
ADMA Biologics ADMA reported fourth-quarter 2025 adjusted earnings per share (EPS) of 21 cents, (excluding stock-based compensation modifications, yield enhancement expense up, voluntary withdrawal
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm